heiDATA

Metrics

207,636 Downloads

Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Publication Year: 2023

41 to 50 of 2,476 Results

Vardarli_Suppl Fig 18.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 123.8 KB - MD5: e49c23bb1823756f90ba710a36a71d52 Suppl. Fig. 18. Forest plot for subgroups of ICI types trials investigating insulin-dependent diabetes mellitus any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 19.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 80.6 KB - MD5: 7a5be4e2d1d4c1805b25946bfbb2a0e1 Suppl. Fig. 19. Forest plot for cumulative meta-analysis for trials investigating insulin-dependent diabetes mellitus any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 1.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 1.2 MB - MD5: 715cdaed20ef88c2c0e8ca4261d863af Suppl. Fig. 1. Risk of bias summary for each included study, n= 80 trials.
Vardarli_Suppl Fig 20.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 123.6 KB - MD5: 6b83ff9a9da2c361ff0b4140ec06b958 Suppl. Fig. 20. Forest plot for subgroups of ICI types trials investigating insulin-dependent diabetes mellitus grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 21.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 120.9 KB - MD5: 2a606fbb196c04b307bf9b66aa039486 Suppl. Fig. 21. Funnel plot for trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 22.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 72.2 KB - MD5: 0c3e0a9c165d70c9ce99c8dffde73b91 Suppl. Fig. 22. Galbraith plot for trials investigating hypothyroidism any under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 23.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 67.9 KB - MD5: 72b2df5a5bf853f41e056ddba64c12af Suppl. Fig. 23. Funnel plot for subgroups of ICI types trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 24.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 63.7 KB - MD5: 6da569546483a744b18f6324e15a470b Suppl. Fig. 24. Funnel plot for trials investigating hypothyroidism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 25.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 66.5 KB - MD5: 24b37ed2883d376999ee0ddce70df0fc Suppl. Fig. 25. Funnel plot for subgroups of ICI types trials investigating hypothyroidism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 26.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 70.5 KB - MD5: bef07fe9ea9a2734957f1416fc5deb13 Suppl. Fig. 26. Galbraith plot for trials investigating hypothyroidism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 18.pdf

Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]

Adobe PDF - 123.8 KB -

Suppl. Fig. 18. Forest plot for subgroups of ICI types trials investigating insulin-dependent diabetes mellitus any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 19.pdf

Adobe PDF - 80.6 KB -

Suppl. Fig. 19. Forest plot for cumulative meta-analysis for trials investigating insulin-dependent diabetes mellitus any grade under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 1.pdf

Adobe PDF - 1.2 MB -

Suppl. Fig. 1. Risk of bias summary for each included study, n= 80 trials.

Vardarli_Suppl Fig 20.pdf

Adobe PDF - 123.6 KB -

Suppl. Fig. 20. Forest plot for subgroups of ICI types trials investigating insulin-dependent diabetes mellitus grade 3-5 under immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 21.pdf

Adobe PDF - 120.9 KB -

Suppl. Fig. 21. Funnel plot for trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 22.pdf

Adobe PDF - 72.2 KB -

Suppl. Fig. 22. Galbraith plot for trials investigating hypothyroidism any under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 23.pdf

Adobe PDF - 67.9 KB -

Suppl. Fig. 23. Funnel plot for subgroups of ICI types trials investigating hypothyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 24.pdf

Adobe PDF - 63.7 KB -

Suppl. Fig. 24. Funnel plot for trials investigating hypothyroidism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 25.pdf

Adobe PDF - 66.5 KB -

Suppl. Fig. 25. Funnel plot for subgroups of ICI types trials investigating hypothyroidism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 26.pdf

Adobe PDF - 70.5 KB -

Suppl. Fig. 26. Galbraith plot for trials investigating hypothyroidism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Add Data

Share Dataverse

Link Dataverse

Reset Modifications